OBJECTIVE: To determine the incidence and characteristics of acute intraocular inflammation after intravitreal bevacizumab injections from a tertiary care retinal practice. DESIGN: Retrospective cohort study. PARTICIPANTS: A consecutive series of patients who had received bevacizumab injections performed by a single surgeon. METHODS: We reviewed the records of all patients with severe anterior chamber inflammation and (or) vitritis after bevacizumab injections. RESULTS: A total of 693 bevacizumab injections were performed on 193 eyes of 173 patients between June 2006 and March 2008. There were a total of 9 cases of acute intraocular inflammation for an incidence of 1.30% (95% CI: 0.69%-2.47%). All patients had a worse visual acuity at the end of follow-up than on injection day. The mean loss of vision was 6.1 lines of Snellen visual acuity; one patient developed inflammation-induced glaucoma which required surgical intervention. CONCLUSIONS: Intravitreal injection of bevacizumab is associated with a low but significant risk of acute intraocular inflammation and may result in significant visual loss.
OBJECTIVE: To determine the incidence and characteristics of acute intraocular inflammation after intravitreal bevacizumab injections from a tertiary care retinal practice. DESIGN: Retrospective cohort study. PARTICIPANTS: A consecutive series of patients who had received bevacizumab injections performed by a single surgeon. METHODS: We reviewed the records of all patients with severe anterior chamber inflammation and (or) vitritis after bevacizumab injections. RESULTS: A total of 693 bevacizumab injections were performed on 193 eyes of 173 patients between June 2006 and March 2008. There were a total of 9 cases of acute intraocular inflammation for an incidence of 1.30% (95% CI: 0.69%-2.47%). All patients had a worse visual acuity at the end of follow-up than on injection day. The mean loss of vision was 6.1 lines of Snellen visual acuity; one patient developed inflammation-induced glaucoma which required surgical intervention. CONCLUSIONS: Intravitreal injection of bevacizumab is associated with a low but significant risk of acute intraocular inflammation and may result in significant visual loss.
Authors: Timothy W Olsen; Xiao Feng; Kathy Wabner; Karl Csaky; Stefan Pambuccian; J Douglas Cameron Journal: Invest Ophthalmol Vis Sci Date: 2011-07-01 Impact factor: 4.799
Authors: Szilárd Kiss; Pravin U Dugel; Arshad M Khanani; Michael S Broder; Eunice Chang; Gordon H Sun; Adam Turpcu Journal: Clin Ophthalmol Date: 2018-08-30
Authors: Edith Poku; John Rathbone; Ruth Wong; Emma Everson-Hock; Munira Essat; Abdullah Pandor; Allan Wailoo Journal: BMJ Open Date: 2014-07-17 Impact factor: 2.692
Authors: Tanya A Camacho-Villegas; María Teresa Mata-González; Walter García-Ubbelohd; Linda Núñez-García; Carolina Elosua; Jorge F Paniagua-Solis; Alexei F Licea-Navarro Journal: Mar Drugs Date: 2018-03-31 Impact factor: 5.118